Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lenabasum - Corbus Pharmaceuticals

Next Previous
X
Search
Drug Profile

Lenabasum - Corbus Pharmaceuticals

Alternative Names: Ajulemic acid; Anabasum; CPL-7075; CT-3; DMH-11C; HU-239; IP-751; JBT-101; Resunab

Latest Information Update: 01 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Massachusetts Medical School
  • Developer Cervelo Pharmaceuticals; Corbus Pharmaceuticals; Indevus Pharmaceuticals
  • Class Anti-inflammatories; Antiasthmatics; Antidotes; Antifibrotics; Antirheumatics; Antispastics; Cannabinoids; Carboxylic acids; Non-opioid analgesics; Skin disorder therapies; Small molecules
  • Mechanism of Action Cannabinoid receptor CB2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis; Dermatomyositis; Systemic scleroderma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Systemic lupus erythematosus

Highest Development Phases

  • Discontinued Cystic fibrosis; Dermatomyositis; Inflammation; Interstitial cystitis; Muscle spasticity; Neuropathic pain; Pain; Poisoning; Pulmonary fibrosis; Rheumatoid arthritis; Systemic lupus erythematosus; Systemic scleroderma

Most Recent Events

  • 10 Nov 2023 Updated efficacy data from the phase III RESOLVE-1 trial in Systemic sclerosis presented at the ACR Convergence 2023 (ACR-ARP-2023)
  • 31 Mar 2023 Discontinued - Phase-III for Dermatomyositis in United Kingdom, Sweden, Poland, South Korea, Italy, Japan, Germany, Czech Republic, Canada, Spain, Hungary, Bulgaria, USA (PO) prior to March 2023
  • 31 Mar 2023 Discontinued - Phase-III for Systemic scleroderma in Israel, Japan, South Korea, USA, Australia, Canada, Netherlands, United Kingdom, Germany, Poland, Spain, Switzerland, Italy (PO) prior to March 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top